Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loratadine-Betamethasone for Severe PAR in Children
NCT00963573Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2003
- Primary completion
- Nov 2006
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, open-label, single-arm trial of loratadine and betamethasone in perennial allergic rhinitis (PAR), sponsored by Merck & Co. Primary endpoint: Efficacy and Safety of loratadine/betamethasone oral solution at Day 6. Started Sep 2003; status: completed.
02
Drugs
loratadinebetamethasone
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00963573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00963573.